Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return of the patient to his home.
Interventions
OTHERPharmaceutical consultation at the hospital
During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
OTHERPharmaceutical consultation at the pharmacy
During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
OTHERFollow-up pharmaceutical consultation at the pharmacy
During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient has signed the consent form. * The patient is affiliated to a health insurance programme * The patient is at least 18 years old (≥). * The patient is admitted to complete hospitalization (for patients in the Hospital and Control groups). * The patient is diagnosed with stage 2 to 4 Chronic Obstructive Pulmonary Disease. The diagnosis as well as the stage of the disease are validated by a pulmonologist at the facility. * The patient has one or more inhaler devices to treat Chronic Obstructive Pulmonary Disease. * The patient returns to his / her home when discharged from hospital (for patients in the Hospital and Control groups). * The patient is available for a follow-up of 12 months.
Exclusion criteria
* The subject participates in another interventional study. * The subject is in an exclusion period determined by a previous study. * The patient is under safeguard of justice. * The subject refuses to sign the consent. * It is not possible to give the patient (or his/her trusted-person) informed information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of exacerbation events | Month 3 | Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of visits to the pulmonologist | Month 3 | — |
| Number of visits to the hospital emergency service | Month 3 | — |
| Number of hospitalisation events | Month 3 | — |
| Medication Possession Ratio | 12 months | unit = percent |
| Number of visits to the attending physician | Month 3 | — |
| Quality of life questionnaire | Month 1 | The quality of life questionnaire BPCO-VQ11 is composed of 11 items. Each item is scored in a 5 point scale. |
| device usage learning curve | 12 months | — |
| satisfaction questionnaire | Month 12 | This questionnaire is composed with 4 questions. Each item is scored in a 4 point scale. |
| Usability score of devices | Month 3 | Score between 0 and 3 |
Countries
France
Outcome results
None listed